Stephanie Han, MD
Radiation Oncology · El Paso, TXNPI 1538169388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,040 of the $22,634 with a category attached, or 84.1%. GSK accounts for 84.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $19,154 and has fallen 99.2% since, to $144 in 2024. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $1331.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$19K
- Cardinal Health 110 LLC$3K
- Tactile Systems Technology Inc$128
- Eisai Inc.$117
- Merit Medical Systems Inc$101
- AstraZeneca$96
- plus $301 from 7 others
Across 4 payments — averaging $222,180 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$889K
What the payments were for
- Consulting fees$2,85013%
- Speaking & faculty fees$19,04084%
- Food & beverage$7443%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $19,040 |
| Cardinal Health 110 LLC | 4 | $2,850 |
| Tactile Systems Technology Inc | 1 | $128 |
| Eisai Inc. | 1 | $117 |
| Merit Medical Systems Inc | 1 | $101 |
| AstraZeneca | 1 | $96 |
| Lilly USA, LLC | 2 | $92 |
| Gilead | 1 | $90 |
| Elekta, Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Novocure Inc. | 1 | $24 |
| Boston Scientific | 1 | $17 |
| Beigene USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENGERIX-B$19,040
- BOOSTRIX$19,040
- Flexitouch Plus$128
- Entre Plus$128
- LENVIMA$117
- SAVI BRACHY$101
How this compares
$22,634 in reported general payments places this provider in the 90th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 590 | $116,738 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 322 | $86,689 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 169 | $49,959 |
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 299 | $22,780 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 119 | $6,750 |
| Naloxone Hcl | 114 | $6,491 |
| TwinrixHepatitis A And B Vaccine/Pf | 45 | $5,221 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 33 | $2,196 |
| Dexamethasone | 64 | $1,237 |
| SsdSilver Sulfadiazine | 52 | $1,069 |
| Azithromycin | 213 | $718 |
| Zolpidem Tartrate | 59 | $498 |
| Doxycycline Hyclate | 16 | $311 |
| Ondansetron OdtOndansetron | 20 | $272 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy, Twinrix | $19,040 | $208,647957 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 418 radiation oncology providers in Texas.
Other radiation oncology in El Paso
- Jameson MendelEl Paso$59K
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.